<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43388">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01705925</url>
  </required_header>
  <id_info>
    <org_study_id>PDX-002-11</org_study_id>
    <nct_id>NCT01705925</nct_id>
  </id_info>
  <brief_title>Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome</brief_title>
  <official_title>Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatrix Medical Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pediatrix Medical Group</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to provide comprehensive follow-up in patients with Long QT
      Syndrome (LQTS) and gain additional information regarding genotype-phenotype correlation and
      effective management and treatment options.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>Adverse Cardiac Events on patients with genotype positive LQT1 who have a normal EKG and absence of symptoms, but a molecular confirmation of LQT1.</measure>
    <time_frame>Enrollment is expected to take approximately 5 years. The patients will be followed until they are no longer cared for by a pediatric cardiology facility (typically post-college) or approximately 21 years of age.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Cardiac Events on patients with both phenotype and genotype positive.</measure>
    <time_frame>Enrollment is expected to take approximately 5 years. The patients will be followed until they are no longer cared for by a pediatric cardiology facility (typically post-college) or approximately 21 years of age.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Long QT Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Children and Young Adults with Genotype Positive Long QT Syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children and/or young adults diagnosed with heterogeneous repolarization disorder who
             have genotype positive Long QT, or

          -  Newly diagnosed mutation positive patients with a confirmed test

        Exclusion Criteria:

          -  Children who are phenotypically positive with no molecular testing

          -  Children that are phenotypically positive but genotype negative
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Cohen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatrix Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Spitzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatrix Medical Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Kelleher, MSHS</last_name>
    <email>amy_kelleher@pediatrix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Pediatric Cardiology Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Cohen, MD</last_name>
      <phone>602-253-6000</phone>
      <email>mitchell_cohen@pediatrix.com</email>
    </contact>
    <investigator>
      <last_name>Mitchell Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Cardiology Associates St. Petersburg Clinic</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge McCormack, MD</last_name>
      <phone>727-767-4200</phone>
      <email>jorge_mccormack@pediatrix.com</email>
    </contact>
    <investigator>
      <last_name>Jorge McCormack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Cardiology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Yabek, MD</last_name>
      <phone>505-848-3700</phone>
      <email>steve_yabek@pediatrix.com</email>
    </contact>
    <investigator>
      <last_name>Steven Yabek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Cardiology Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnold Fenrich, MD</last_name>
      <phone>512-480-0143</phone>
      <email>arnold_fenrich@pediatrix.com</email>
    </contact>
    <investigator>
      <last_name>Arnold Fenrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>October 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Long QT Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
